- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00872430
Laxative Effectiveness of a Phytotherapeutic Tea
June 16, 2009 updated by: Hospital de Clinicas de Porto Alegre
Laxative Effectiveness of a Phytotherapeutic Tea: A Randomized Placebo-Controlled Clinical Trial
The aim of this study is to evaluate the efficacy and safety of a phytotherapeutic laxative tea, composed by Pimpinella anisum, Foeniculum vulgare, Sambucus nigra and Cassia angustifolia, in a randomized crossover placebo-controlled clinical trial in patients with chronic constipation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The Klein Laxative Tea is a pharmaceutical phytotherapeutic product that's been used for several years in Brazil for the treatment of constipation.
This product contains fruit of Pimpinella anisum (green anises), fruit of Foeniculum vulgare (fennel), flowers of Sambucus nigra (elder tree) and flowers of Cassia angustifolia (senna).
In spite of the beneficial effects of its components, separately demonstrated in vitro, it never had its effectiveness appraised in a randomized clinical trial.The purpose of this study was to evaluate the efficacy and safety of this product in a randomized crossover placebo-controlled clinical trial.
Twenty patients presenting with the criteria of the American Association of Gastroenterology for chronic constipation were included, and concluded a two-phase crossover study.
The primary endpoint was the evaluation of the intestinal transit time measured through radiological technique.
The secondary endpoints were the number of evacuations, subjective impression of the quality in the intestinal habit, quality of life appraised through WHOQOL-brief and adverse effects.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazil, 90035903
- Hospital de Clinicas de Porto Alegre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- patients with 18 to 55 years old with chronic constipation according to the criteria of the American Association of Gastroenterology (AAG);
- patients should present good understanding and collaboration capacity, an not be in use of other medications with effects on the intestinal habit;
- patients with no abnormalities in the exams;
- willing to sign a written informed consent;
- women in fertile age should make use of appropriate anti-conception.
Exclusion Criteria:
- pregnant or breast feeding women;
- patients with history of abuse of alcohol or use of drugs;
- significant or not-controlled disease, except constipation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Placebo/Laxative tea crossover
This arm received placebo in the first period and laxative tea in the second period (after washout period of 9 days).
|
In order to produce similar taste and color, 7 drops of caramel color and 10 drops of orange essence were mixed into 1.6 liters of boiling water.
The patients received 150 ml of placebo 3 times a day for 5 days.
The laxative tea was prepared using 1 gram of grinded plant into 150 ml of water, left under infusion by 5 minutes.
Patients received 150 ml of tea 3 times a day for 5 days.
Other Names:
|
ACTIVE_COMPARATOR: Laxative tea/Placebo crossover
This arm received laxative tea in the first intervention period and placebo in the second intervention period (after washout period of 9 days).
|
In order to produce similar taste and color, 7 drops of caramel color and 10 drops of orange essence were mixed into 1.6 liters of boiling water.
The patients received 150 ml of placebo 3 times a day for 5 days.
The laxative tea was prepared using 1 gram of grinded plant into 150 ml of water, left under infusion by 5 minutes.
Patients received 150 ml of tea 3 times a day for 5 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intestinal Transit Time
Time Frame: day 3 and day 17
|
Radiologic technique consisting of the ingestion of radiopaque markers, followed by a simple x-ray of the abdomen on day 3 of each intervention period.
Standard formula, regarding markers ingested, time of ingestion and markers still present on the colon (counted by radiologist unaware of the treatment allocation), provided transit time.
|
day 3 and day 17
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients With no Evacuation After Each Intervention Period
Time Frame: day 5 and day 19
|
The number of patients who had not evacuated on day 5 of each intervention period was obtained using questions 1 and 9 of the Scale for Assessment of Constipation Symptoms based on: 1) How many times have you had a bowel movement in the last 24 hours?; 9) Classification of bowel habit on a scale of 1 (terrible) to 5 (excellent).
|
day 5 and day 19
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Paulo D picon, Coordinator, Hospital de Clinicas de Porto Alegre
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2002
Primary Completion (ACTUAL)
December 1, 2002
Study Completion (ACTUAL)
June 1, 2003
Study Registration Dates
First Submitted
November 6, 2008
First Submitted That Met QC Criteria
March 30, 2009
First Posted (ESTIMATE)
March 31, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
June 17, 2009
Last Update Submitted That Met QC Criteria
June 16, 2009
Last Verified
June 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 02121
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Constipation
-
usMIMA S.L.CompletedConstipation | Constipation Chronic Idiopathic | Constipation; NeurogenicSpain, United Kingdom
-
SK Life Science, Inc.CompletedChronic Constipation | Functional ConstipationUnited States
-
Cairo UniversityUnknownChronic Idiopathic Constipation | Functional ConstipationEgypt
-
AbbVieIronwood Pharmaceuticals, Inc.RecruitingFunctional Constipation (FC) | Chronic Idiopathic Constipation (CIC)United States, United Kingdom, Bulgaria, Netherlands
-
Air Force Military Medical University, ChinaRecruitingChronic ConstipationChina
-
Yokohama City UniversityRecruiting
-
TakedaThe Organization of Teratology Information SpecialistsRecruiting
-
TakedaUC San Diego Human Milk Research BiorepositoryRecruiting
-
International University of Health and WelfareTerminated
-
Astellas Pharma IncCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States